Suchergebnisse

Tax 2010/2011 For Dummies®; Contents at a Glance; Table of Contents; Introduction; About This Book; Conventions Used in This Book; What You're Not to Read; Foolish Assumptions; How This Book Is Organised; Icons Used in This Book; Where to Go from Here; Part I: Tax Facts; Chapter 1: Thinking About Tax; Chapter 2: Understanding the Legal Framework; Chapter 3: Self Assessing; Chapter 4: Working Out How Much Income Tax Is Due; Part II: Tax Through Your Ages; Chapter 5: Supporting Children; Chapter 6: Making Tax-Efficient Investments; Chapter 7: Investing in Property. - Chapter 8: Passing On Your WealthPart III: Pensions and Benefits; Chapter 9: Understanding UK Pensions; Chapter 10: Paying Tax on Your Pensions; Chapter 11: Looking at State Benefits and Tax; Part IV: Working for Someone Else; Chapter 12: PAYEing Tax in Employment; Chapter 13: Receiving Expenses and Benefits; Chapter 14: Sharing Your Employer's Fortunes; Part V: Working for Yourself; Chapter 15: Starting a Business; Chapter 16: Running a Business; Chapter 17: Incorporating Your Business; Part VI: The Part of Tens; Chapter 18: Ten Tax-Saving Tips. - Chapter 19: Ten Tips for Dealing with HM Revenue & CustomsChapter 20: Ten Tips for Starting and Running Your Own Business; Appendix; HMRC Helplines; Pensions Guidance; Benefit Rates; Index

Substandard and falsified medicines pose significant risks to global health, including increased deaths, prolonged treatments, and growing drug resistance. Antimalarials are one of the most common medications to be of poor quality in low- and middle-income countries. We assessed the health and economic impact of substandard and falsified antimalarials for children less than 5 years of age in the Democratic Republic of the Congo, which has one of the world's highest malaria mortality rates. We developed an agent-based model to simulate patient care-seeking behavior and medicine supply chain processes to examine the impact of antimalarial quality in Kinshasa province and Katanga region. We simulated the impact of potential interventions to improve medicinal quality, reduce stockouts, or educate caregivers. We estimated that substandard and falsified antimalarials are responsible for $20.9 million (35% of $59.6 million; 95% CI: $20.7–$21.2 million) in malaria costs in Kinshasa province and $130 million (43% of $301 million; $129–$131 million) in malaria costs in the Katanga region annually. If drug resistance to artemisinin were to develop, total annual costs of malaria could increase by $17.9 million (30%; $17.7–$18.0 million) and $73 million (24%; $72.2–$72.8 million) in Kinshasa and Katanga, respectively. Replacing substandard and falsified antimalarials with good quality medicines had a larger impact than interventions that prevented stockouts or educated caregivers. The results highlight the importance of improving access to good quality antimalarials to reduce the burden of malaria and mitigate the development of antimalarial resistance.